YBX1 and ovarian carcinoma: The high expression level of YBX1 is a poor prognostic marker in patients with breast cancer (Habibi et al., 2008), ovarian cancer (Kamura et al., 1999), prostate cancer (Giménez‐Bonafé et al., 2004), and other human malignancies (Kosnopfel et al., 2014).